Please login to the form below

Not currently logged in

Bayer agrees $2.9bn deal for Algeta to get Xofigo control

Raises initial offer to buy Norweigan pharma company


Bayer has reached an agreement to buy Norwegian pharma company Algeta after raising its offer to around $2.9bn.

News of Bayer's interest in Algeta - which developed recently-approved prostate cancer therapy Xofigo (radium Ra 223 dichloride) - first emerged in November when the offer was reported be NOK 336 per share, valuing the company at around $2.4bn.

Management of the two companies have now agreed a NOK 362 per share deal for Algeta, which will now be offered on a voluntary basis to the Norwegian firm's shareholders. The bid represents a premium of 37 per cent over Algeta's closing price on November 25 when the initial offer was made. This morning Algeta was trading at around NOK 359.

Xofigo - which delivers localised radiotherapy to tumours via a calcium mimicking radioactive isotope that is taken up by cancer cells - was approved in the EU last month, having been given a green light in the US in May, three months ahead of schedule.

The therapy is used for the treatment of men with castration-resistant prostate cancer (CRPC) who also have symptomatic bone metastases and no known visceral metastases, and racked up third quarter sales of around €12m ($17m) in the third quarter. Algeta chief executive Andrew Kay said last month the drug had shown "excellent momentum" thanks to rapid endorsement by the US National Cancer Network.

Bayer has already predicted that Xofigo could develop into a blockbuster product if approved in additional indications, and chief executive Marijn Dekkers said today that the company is "absolutely convinced of the potential of this drug and the underlying technology to provide patients with innovative treatment options".

The statement reinforces the view that Bayer views the Algeta acquisition as a platform rather than a product purchase, with additional radiopharmaceuticals in its pipeline including a programme in breast cancer.

Bayer recently announced its intention to start a study looking at combining Xofigo with anti-androgens - such as Johnson & Johnson's Zytiga (abiraterone acetate) and Astellas/Medivation's Xtandi (enzalutamide) - and implementing therapy as soon as patients are diagnosed with CRPC.

In addition to radium 223 dichloride, the Norwegian company also has a research project looking at thorium-227, an isotope that could have utility in a broader range of cancers, with a lead candidate now approaching the clinic.

The deal is expected to close during the first quarter of 2014.

Article by
Phil Taylor

19th December 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Complete True Life

Complete True Life is a progressive new agency specializing in the validation of insights-led and generation of evidence-based real-world studies...

Latest intelligence

How do you solve a problem like non-adherence? Part 2
Following her previous piece on patient medical non-adherence, Head of Customer Experience Elisa del Galdo takes a look at the different patient personas that emerge during the diagnosis and treatment...
The patient will see you now
GCI Health’s Laura Starr and Chris Bath report on how the dawning era of mobile tech and the ‘Internet of Things’ has transformed the health and wellness arena....
When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...